Overview
Avadel Pharmaceuticals plc is an Ireland-based biopharmaceutical company, primarily engaged in the development and commercialization of proprietary pharmaceutical products. The company specializes in hospital and other therapeutic products within the United States. One of its key projects involves the development of FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of narcolepsy, which is currently under review by the U.S. Food and Drug Administration (FDA). Avadel’s strategy focuses on leveraging its proprietary drug delivery technologies to provide novel formulations that aim to improve patient outcomes and enhance the overall patient experience, addressing both existing and unmet medical needs within the pharmaceutical sector.
Basic Stats
The share price of Avadel Pharmaceuticals plc as of September 5, 2025 is $15.77 / share. This is an increase of 6.84% from the prior week. The market cap (or net worth) of Avadel Pharmaceuticals plc as of September 5, 2025 is $1,526.17 MM.
The Factor Analysis chart (below right) shows a view of Avadel Pharmaceuticals plc from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 1,526.17 MM |
| EV | 1,500.06 MM |
| Shares Out. | 96.78 MM |
| Earnings Date | |
| EPS (TTM) | -0.03 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.37 |
| Short Shares Avail. | 3.60 MM |
| Short Interest | 10.12 MM |
| Short Float | 12.55 % |
| Days to Cover | 6.48 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | 7.83 % |
| Volatility (1 yr) | 0.62 |
| Beta | 1.54 |
| Sharpe Ratio (1 yr) | 0.06 |
| Sortino Ratio (1 yr) | 0.09 |
| PE Ratio | -522.13 |
| Price/Book | 16.82 |
| Price/TBV | 20.66 |
| Book/Market | 0.06 |
| EBIT/EV | -0.00 |
| EBIT(3yr avg)/EV | -0.06 |
| ROA | -0.02 |
| ROE | -0.04 |
| ROIC | -0.02 |
| CROIC | 0.26 |
| OCROIC | 0.04 |
| Implied Volatility | 46.28 % |
| Put/Call OI Ratio | 0.12 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Avadel Pharmaceuticals plc is $19.51. The forecasts range from a low of $16.16 to a high of $25.20. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Avadel Pharmaceuticals plc. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-02-07 | Needham | Buy | Reiterate | |
| 2023-02-07 | HC Wainwright & Co. | Buy | Reiterate | |
| 2022-11-30 | Jefferies | Hold | Buy | Upgrade |
| 2022-11-21 | Needham | Buy | Maintains | |
| 2022-08-11 | SVB Leerink | Outperform | Maintains | |
| 2022-08-10 | Needham | Buy | Maintains | |
| 2022-08-10 | Jefferies | Buy | Hold | Downgrade |
| 2022-05-31 | Needham | Buy | Maintains | |
| 2022-05-27 | SVB Leerink | Outperform | Maintains | |
| 2022-05-27 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-01-11 | Needham | Buy | Maintains | |
| 2021-09-23 | Needham | Buy | Initiate | |
| 2021-03-10 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-07-21 | SVB Leerink | Outperform | Initiate | |
| 2020-06-30 | HC Wainwright & Co. | Buy | Initiate | |
| 2020-05-04 | Piper Sandler | Overweight | Maintains | |
| 2020-04-03 | Jefferies | Buy | Initiate | |
| 2020-03-12 | Stifel | Buy | Initiate | |
| 2020-02-26 | Piper Sandler | Overweight | Initiate | |
| 2020-01-30 | Craig-Hallum | Buy | Initiate | |
| 2019-09-24 | Laidlaw & Co. | Buy | Maintains | |
| 2019-06-14 | Ladenburg Thalmann | Neutral | Buy | Upgrade |
| 2019-02-08 | Ladenburg Thalmann | Buy | Neutral | Downgrade |
| 2018-11-06 | Laidlaw & Co. | Buy | Hold | Downgrade |
| 2023-02-27 | Oppenheimer | Outperform | Maintains | |
| 2023-02-24 | Needham | Buy | Maintains | |
| 2023-03-23 | HC Wainwright & Co. | Buy | Maintains | |
| 2023-04-03 | Oppenheimer | Outperform | Reiterate | |
| 2023-04-03 | Needham | Buy | Reiterate | |
| 2023-04-17 | Needham | Buy | Maintains | |
| 2023-05-02 | Ladenburg Thalmann | Buy | Maintains | |
| 2023-05-02 | Oppenheimer | Outperform | Maintains | |
| 2023-05-02 | Needham | Buy | Maintains | |
| 2023-05-02 | HC Wainwright & Co. | Buy | Maintains | |
| 2023-04-28 | Needham | Buy | Reiterate | |
| 2023-05-02 | LifeSci Capital | Outperform | Maintains | |
| 2023-05-30 | Needham | Buy | Reiterate | |
| 2023-06-12 | Oppenheimer | Outperform | Outperform | Reiterate |
| 2023-12-20 | Needham | Buy | Buy | Maintains |
| 2023-06-30 | Oppenheimer | Outperform | Market Outperform | Maintains |
| 2023-06-30 | Needham | Buy | Buy | Reiterate |
| 2024-02-06 | UBS | Buy | Initiate | |
| 2023-08-09 | Needham | Buy | Reiterate | |
| 2023-10-04 | Needham | Buy | Buy | Reiterate |
| 2023-07-05 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-08-10 | Piper Sandler | Overweight | Overweight | Maintains |
| 2023-08-10 | Needham | Buy | Buy | Reiterate |
| 2023-08-10 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-09-25 | Needham | Buy | Buy | Reiterate |
| 2023-11-09 | Needham | Buy | Buy | Maintains |
| 2024-03-05 | Craig-Hallum | Buy | Buy | Maintains |
| 2024-03-05 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-03-05 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-03-05 | Piper Sandler | Overweight | Overweight | Maintains |
| 2024-03-05 | Needham | Buy | Buy | Maintains |
| 2024-04-09 | Needham | Buy | Buy | Reiterate |
| 2024-05-09 | Needham | Buy | Buy | Reiterate |
| 2024-05-08 | Needham | Buy | Buy | Reiterate |
| 2024-05-09 | Craig-Hallum | Buy | Buy | Maintains |
| 2024-05-09 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-08-09 | Needham | Buy | Buy | Reiterate |
| 2024-10-21 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-10-31 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-10-31 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-10-31 | Needham | Buy | Buy | Reiterate |
| 2025-01-09 | Needham | Buy | Buy | Maintains |
| 2024-08-29 | Needham | Buy | Buy | Reiterate |
| 2024-08-28 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-13 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-11-13 | Needham | Buy | Buy | Reiterate |
| 2025-02-11 | Deutsche Bank | Buy | Initiate | |
| 2024-09-04 | Needham | Buy | Buy | Reiterate |
| 2024-10-18 | Needham | Buy | Buy | Reiterate |
| 2025-04-09 | Needham | Buy | Buy | Reiterate |
| 2025-01-10 | Piper Sandler | Overweight | Overweight | Maintains |
| 2025-01-10 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-03-04 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-12 | Needham | Buy | Buy | Reiterate |
| 2025-03-03 | Needham | Buy | Buy | Reiterate |
| 2025-01-13 | UBS | Buy | Buy | Maintains |
| 2025-03-04 | Needham | Buy | Buy | Reiterate |
| 2025-08-21 | UBS | Buy | Buy | Maintains |
| 2025-05-08 | Needham | Buy | Buy | Reiterate |
| 2025-09-05 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-08-08 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-09-03 | Wells Fargo | Equal-Weight | Initiate |
